Category: Drug Discovery
Drug Discovery market research reports by DelveInsight
-
5-HT1B Antagonist - Pipeline Insight, 2025
“5-HT1B Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 5-HT1B Antagonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of ... Read More
-
Allergic Rhinitis - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights In 2023, the Allergic Rhinitis Market Size was highest in the US among the 7MM, accounting for approximately USD 3,600 million which is further expected to increase by 2034. In 2023, the prevalence of Allergic rhinitis was highest in Japan among the 7MM, accounting for approximately 6 ... Read More
-
TGF-Beta Inhibitor - Pipeline Insight, 2025
“TGF-Beta Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across TGF-Beta Inhibitor development. The report provides detailed coverage of the pipeline landscape for this mechanism ... Read More
-
Interleukin-8 (IL-8) Inhibitor - Pipeline Insight, 2025
“Interleukin-8 (IL-8) Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Interleukin-8 (IL-8) Inhibitor development. The report provides detailed coverage of the pipeline lands ... Read More
-
Interleukin-4 (IL-4) Inhibitor - Pipeline Insight, 2025
“Interleukin-4 (IL-4) Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Interleukin-4 (IL-4) Inhibitor development. The report provides detailed coverage of the pipeline lands ... Read More
-
Interleukin-12 (IL-12) Inhibitor - Pipeline Insight, 2025
“Interleukin-12 (IL-12) Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Interleukin-12 (IL-12) Inhibitor development. The report provides detailed coverage of the pipeline l ... Read More
-
Interleukin-13 (IL-13) Inhibitor - Pipeline Insight, 2025
“Interleukin-13 (IL-13) Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Interleukin-13 (IL-13) Inhibitor development. The report provides detailed coverage of the pipeline l ... Read More
-
Anaplastic lymphoma kinase inhibitors - Pipeline Insight, 2025
DelveInsight’s, “Anaplastic Lymphoma Kinase (ALK) Inhibitors - Pipeline Insight, 2025” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Anaplastic Lymphoma Kinase (ALK) Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and non ... Read More
-
Amyloid Protein Blockers - Pipeline Insight, 2025
“Amyloid Protein Blockers - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Amyloid Protein Blockers development. The report provides detailed coverage of the pipeline landscape for thi ... Read More
-
Adenosine A1 Receptor Agonist - Pipeline Insight, 2025
“Adenosine A1 Receptor Agonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Adenosine A1 Receptor Agonist development. The report provides detailed coverage of the pipeline landsca ... Read More
-
5-HT4 Agonist - Pipeline Insight, 2025
“5-HT4 Agonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 5-HT4 Agonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, ... Read More
-
5-HT1 Antagonist - Pipeline Insight, 2025
“5-HT1 Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 5-HT1 Antagonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of a ... Read More
-
30S Ribosomal Subunit (30S RNA) Inhibitor - Pipeline Insight, 2025
“30S Ribosomal Subunit (30S RNA) Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 30S Ribosomal Subunit (30S RNA) Inhibitor development. The report provides detailed coverage ... Read More
-
1,3-Beta-Glucan Synthase Inhibitor - Pipeline Insight, 2025
“1,3-Beta-Glucan Synthase Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 1,3-Beta-Glucan Synthase Inhibitor development. The report provides detailed coverage of the pipeli ... Read More
-
20s Proteasome Inhibitor - Pipeline Insight, 2025
“20s Proteasome Inhibitor - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across 20s Proteasome Inhibitor development. The report provides detailed coverage of the pipeline landscape for thi ... Read More
-
Neuroendocrine tumors - Pipeline Insight, 2025
DelveInsight’s, “Neuroendocrine tumors - Pipeline Insight, 2025” report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in Neuroendocrine tumors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers th ... Read More
-
Transient Receptor Potential Cation Channel, Subfamily A, Member 1 (TRPA1) Antagonist - Pipeline Insight, 2025
“Transient Receptor Potential Cation Channel, Subfamily A, Member 1 (TRPA1) Antagonist - Pipeline Insight, 2025” report by DelveInsight offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Transient Receptor Potential Cation Channel, Sub ... Read More
-
Post-Bariatric Hypoglycemia - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights In 2023, the United States accounted for approximately 90% of the total Post-Bariatric hypoglycemia market size within the seven major markets. Post-Bariatric hypoglycemia is the development of hypoglycemia (low blood sugar) following bariatric surgery, such as gastric bypass or sleev ... Read More
-
WHIM Syndrome - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights WHIM syndrome is a rare genetic disorder caused by CXCR4 mutations, leading to immunodeficiency, warts, hypogammaglobulinemia, and myelokathexis. In 2023, the diagnosed prevalent population in the 7MM was estimated to be around 179 individuals. WHIM is a significant health issue in th ... Read More
-
Sickle Cell Disease (SCD) - Market Insight, Epidemiology, and Market Forecast - 2034
Key Highlights Sickle cell disease (SCD) is a genetic blood disorder characterized by the presence of abnormal hemoglobin, causing red blood cells to become sickle-shaped. SCD is a global health concern, particularly prevalent in populations with African, Middle Eastern, Mediterranean, and South Asi ... Read More
-
Idiopathic Inflammatory Myositis - Market Insights, Epidemiology, and Market Forecast - 2034
Key Highlights According to DelveInsight’s estimates, in 2023, there were approximately 191,589 diagnosed prevalent cases of idiopathic inflammatory myositis in the 7MM. Of these, the United States accounted for 48% of the cases, while EU4 and the UK accounted for nearly 38% and Japan represented 14 ... Read More
-
Refractory Metastatic Melanoma - Pipeline Insight, 2025
DelveInsight’s, “Refractory Metastatic Melanoma - Pipeline Insight, 2025” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Refractory Metastatic Melanoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It ... Read More
-
Guillain-Barré Syndrome (GBS) - Pipeline Insight, 2025
DelveInsight’s, “Guillain-Barré Syndrome (GBS) - Pipeline Insight, 2025” report provides comprehensive insights about 2+ companies and 3+ pipeline drugs in Guillain-Barré Syndrome (GBS) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It al ... Read More
-
Chronic inflammatory demyelinating polyneuropathy (CIDP)- Pipeline Insight, 2025
DelveInsight’s, “Chronic inflammatory demyelinating polyneuropathy (CIDP)- Pipeline Insight, 2025” report provides comprehensive insights about 2+ companies and 4+ pipeline drugs in Chronic inflammatory demyelinating polyneuropathy (CIDP)pipeline landscape. It covers the pipeline drug profiles, incl ... Read More
-
Androgen receptor antagonists - Pipeline Insight, 2025
DelveInsight’s, “Androgen receptor antagonists - Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Androgen receptor antagonists pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It ... Read More
Research Assistance
